Fabricating a PDA-Liposome Dual-Film Coated Hollow Mesoporous Silica Nanoplatform for Chemo-Photothermal Synergistic Antitumor Therapy

• Published in: Pharmaceutics Vol. 15; no. 4; p. 1128
• Main Authors: Fan, Chuanyong, Wang, Xiyu, Wang, Yuwen, Xi, Ziyue, Wang, Yuxin, Zhu, Shuang, Wang, Miao, Xu, Lu
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.04.2023; MDPI
• Subjects: Biocompatibility; Biotechnology industry; Breast cancer; Cancer; Cancer therapies; Carbon; Chemical properties; chemo-photothermal therapy; Chemotherapy; Dopamine; Dosage and administration; doxorubicin; Drug delivery systems; Drug resistance; Drugs; Efficiency; Ethanol; Graphene; Health aspects; hollow mesoporous silica; Lipids; liposome-TPGS; Liposomes; Materials; Nanomaterials; Nanoparticles; Permeability; Photochemotherapy; polydopamine; Polyethylene glycol; Radiation therapy; Testing; Tumors; Vehicles; China; hollow mesoporous silica; liposome-TPGS; polydopamine; doxorubicin; chemo-photothermal therapy
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics15041128

In this study, we synthesized hollow mesoporous silica nanoparticles (HMSNs) coated with polydopamine (PDA) and a D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS)-modified hybrid lipid membrane (denoted as HMSNs-PDA@liposome-TPGS) to load doxorubicin (DOX), which achieved the integration of chemotherapy and photothermal therapy (PTT). Dynamic light scattering (DLS), transmission electron microscopy (TEM), N2 adsorption/desorption, Fourier transform infrared spectrometry (FT-IR), and small-angle X-ray scattering (SAXS) were used to show the successful fabrication of the nanocarrier. Simultaneously, in vitro drug release experiments showed the pH/NIR-laser-triggered DOX release profiles, which could enhance the synergistic therapeutic anticancer effect. Hemolysis tests, non-specific protein adsorption tests, and in vivo pharmacokinetics studies exhibited that the HMSNs-PDA@liposome-TPGS had a prolonged blood circulation time and greater hemocompatibility compared with HMSNs-PDA. Cellular uptake experiments demonstrated that HMSNs-PDA@liposome-TPGS had a high cellular uptake efficiency. In vitro and in vivo antitumor efficiency evaluations showed that the HMSNs-PDA@liposome-TPGS + NIR group had a desirable inhibitory activity on tumor growth. In conclusion, HMSNs-PDA@liposome-TPGS successfully achieved the synergistic combination of chemotherapy and photothermal therapy, and is expected to become one of the candidates for the combination of photothermal therapy and chemotherapy antitumor strategies.